{"nctId":"NCT02200770","briefTitle":"N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","startDateStruct":{"date":"2015-04-01","type":"ACTUAL"},"conditions":["Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders"],"count":231,"armGroups":[{"label":"Placebo/Inebilizumab","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Inebilizumab","Other: Placebo"]},{"label":"Inebilizumab/Inebilizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Inebilizumab","Other: Placebo"]}],"interventions":[{"name":"Inebilizumab","otherNames":["MEDI-551"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women 18 years or older with diagnosis of NMO/NMOSD\n2. Confirmation of NMO/NMOSD status:\n\n   1. AQP4-IgG sero-positive NMO/NMOSD with at least one attack requiring rescue therapy in the last year or two attacks requiring rescue therapy in the last 2 years\n   2. AQP4-IgG sero-negative NMO with at least one attack requiring rescue therapy in the last year or two attacks requiring rescue therapy in the last 2 years\n3. Able and willing to give written informed consent and comply with the requirements of the study protocol.\n4. EDSS \\<= 7.5 (8 in special circumstances)\n5. Men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product.\n\nExclusion Criteria:\n\n1. Lactating and pregnant females\n2. Treatment with any investigational agent within 4 weeks of screening\n3. Known history of a severe allergy or reaction to any component of the investigational product formulation or history of anaphylaxis following any biologic therapy.\n4. Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization.\n5. History of alcohol, drug, or chemical abuse, or a recent history of such abuse \\< 1 year prior to randomization\n6. Receipt of the following at any time prior to randomization:\n\n   1. Alemtuzumab\n   2. Total lymphoid irradiation\n   3. Bone marrow transplant\n   4. T-cell vaccination therapy\n7. Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.\n8. Receipt of intravenous immunoglobulin (IVIG) within 1 month prior to randomization.\n9. Receipt of any of the following within 3 months prior to randomization:\n\n   1. Natalizumab (TysabriÂ®).\n   2. Cyclosporin\n   3. Methotrexate\n   4. Mitoxantrone\n   5. Cyclophosphamide\n   6. Tocilizumab\n   7. Eculizumab\n10. History of Hepatitis B and/or Hepatitis C (Hep B/C at screening)\n11. Known history of a primary immunodeficiency (congenital or acquired) or an underlying condition such as human immunodeficiency virus (HIV) infection\n12. History of malignancies, apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy \\> 3 months prior to randomization\n13. Any concomitant disease other than NMO/NMOSD that required treatment with oral or intravenous steroids at doses over 20 mg a day for over 21 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP","description":"The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria. These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide. Only attacks positively adjudicated by the AC were used for the primary analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP","description":"EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS). It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS). A negative change from baseline indicates improvement. A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP","description":"Low-contrast visual acuity test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters. Binocular score is the number of letters read correctly on an eye chart using both eyes simultaneously. The total score ranges from 0-70. Higher score indicates better vision.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.442","spread":"1.217"},{"groupId":"OG001","value":"1.576","spread":"0.935"}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP","description":"The number of new gadolinium-enhancing lesions and new or enlarging T2 lesions were measured by MRI of the brain, optic nerve, and spinal cord.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.3"},{"groupId":"OG001","value":"1.6","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Number of NMOSD-related In-patient Hospitalizations During RCP","description":"Participants with relapsing NMOSD have recurrent attacks that can be severe and result in blindness, paralysis, and even death and consequently, such attacks frequently result in in-patient hospitalizations. In-patient hospitalization is defined as a stay in hospital that goes beyond midnight of the first day of admission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.7"},{"groupId":"OG001","value":"1.0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Annualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab","description":"Annualized attack rate is defined as total number of AC-determined attacks divided by total person years. Total person-years is calculated as the sum of the person-years for individual participant. Person-year for individual participant = (Date of last day before safety follow-up period - first inebilizumab dose date +1)/365.25. Annualized AC-determined NMOSD attack rate during any exposure to inebilizumab (in RCP and OLP) is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.086","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) During RCP","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the RCP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs and TESAEs During OLP","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs and TESAEs During SFP (Open-label Population)","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. Participant who prematurely discontinued from the RCP or OLP entered in the SFP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs and TESAEs During SFP (Non-OLP Population)","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. The SFP started when a participant prematurely discontinues from the RCP or OLP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During RCP","description":"Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during RCP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During OLP","description":"Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during OLP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Maximum Serum Concentration (Tmax) of Inebilizumab (During RCP)","description":"Time to maximum serum concentration of inebilizumab during RCP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Concentration (Cmax) of Inebilizumab (During RCP)","description":"Maximum observed serum concentration of inebilizumab during RCP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":"37.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":"45.4"}]}]}]},{"type":"SECONDARY","title":"Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab (During RCP)","description":"Area under the serum concentration time curve of the dosing interval (AUC0-14d) of inebilizumab during RCP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"667","spread":"31.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"967","spread":"39.6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During RCP)","description":"Number of participants with positive ADA titer to inebilizumab during RCP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During OLP)","description":"Number of participants with positive ADA titer to inebilizumab in OLP is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":56},"commonTop":["Urinary tract infection","Nasopharyngitis","Headache","Arthralgia","Upper respiratory tract infection"]}}}